checkAd

    EQS-Adhoc  129  0 Kommentare Heidelberg Pharma AG announces updated guidance

    Für Sie zusammengefasst
    • Heidelberg Pharma AG updates guidance for 2024
    • Sales and income expected to be lower
    • Operating expenses and cash requirements adjusted

    EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Change in Forecast
    Heidelberg Pharma AG announces updated guidance

    18-Jun-2024 / 13:47 CET/CEST
    Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.


    Ad hoc announcement

    Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014

    Heidelberg Pharma AG Announces Updated Guidance

    Ladenburg, Germany, 18 June 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it has adjusted its guidance for the current fiscal year published on 25 March 2024.

    The Heidelberg Pharma Group expects for the financial year 2024 sales and other income between EUR 9.0 million and EUR 12.0 million (previously: EUR 11.0 million to EUR 15.0 million). The reason for the lower sales is that expected sales are likely to be delayed due to developments at the license partners. Operating expenses will remain between EUR 36.0 million and EUR 40.0 million. Based on these adjustments, an operating result (EBIT) between EUR -25.5 million and EUR -29.5 million is expected (previously: EUR -23.5 million to EUR -27.5 million).

    For 2024, Heidelberg Pharma anticipates cash requirements of EUR 18.0 million to EUR 22.0 million (previously: EUR 28.0 million to EUR 32.0 million). Monthly cash consumption is expected to range between EUR 1.5 million and EUR 1.8 million per month (previously: EUR 2.3 million and EUR 2.7 million). Based on the existing planning and available funds, the company's financing is secured until mid-2025.

    Taking into account a further expected payment of USD 75.0 million from HealthCare Royalty, the company assumes that financing will be available until the end of 2026.



    End of Inside Information

    Information and Explanation of the Issuer to this announcement:

    About Heidelberg Pharma

    Heidelberg Pharma develops novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-Adhoc Heidelberg Pharma AG announces updated guidance EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Change in Forecast Heidelberg Pharma AG announces updated guidance 18-Jun-2024 / 13:47 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, …

    Schreibe Deinen Kommentar

    Disclaimer